Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
RNA and DNA flipons in health and disease
Flipons are the next step in DNA research. What they are, their role in DNA and RNA coding, their impact on medical science, and their relation to the immune system are discussed here.
High-resolution snapshots of antibody repertoires as potential correlates of protection
Klaus Eyer from ETH Zurich describes high-resolution snapshots of antibody repertoires as potential correlates of protection.
tRNA: The operational RNA code and protein folding
Charles W. Carter, Jr., from the Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, relates molecular recognition used in genetic coding to structures of aminoacyl-tRNA synthetases and their cognate tRNAs.
Drug repositioning using multiple gene expression profiles
Chuo University’s Professor Y-h. Taguchi places focus on drug repositioning using multiple gene expression profiles
AI and modern experimental biology: A historical perspective
Ute Deichmann, Director of the Jacques Loeb Centre for the History and Philosophy of the Life Sciences at Ben-Gurion University of the Negev, discusses the adoption and limitations of Artificial Intelligence within modern experimental biology.
Personalized medicine: “Tyranny of the gene”
Dr Priya Hays, Ph.D., CEO/Science Writer at Hays Documentation Specialists, LLC, responds to “Tyranny of the Gene.” Is personalized medicine a threat to public health? Not really, but yes, it’s an argument for price controls and perhaps more regulations; we hear.
Understanding T lymphocytes inner workings to harness therapeutic potential
Leslie J. Berg, PhD from the University of Colorado, Anschutz School of Medicine, sheds light on understanding the inner workings of T lymphocytes to harness their therapeutic potential.
Harnessing redox power for biotechnological application in purple non-sulphur bacteria
Here we explore purple non-sulfur bacteria (PNSB) and some of its biotech applications, with a focus on how these applications have been enhanced by manipulating the flow of reducing power.
Controlling ovarian cancer: An introduction to detection and treatment
With current strategies proving inadequate, what needs to be done is to further the research into detecting, treating, and controlling ovarian cancer.
Probing the individuality of cells and molecules
Sotaro Uemura, Professor at the University of Tokyo, probes the individuality of cells and molecules.
Options for stroke survivors: From stroke to conventional therapy
Discovery of novel treatment options for stroke survivors – requirements for implanted systems.
Innovative gene therapy approaches for brain tumour-related epilepsy
Professor Mark Cunningham and Dr Kate Connor from Trinity College Dublin discuss the burden of brain tumour-related epilepsy and why novel therapies are urgently needed to improve the quality of life for those affected.
Gnotobiotic pig models: Illuminating the enigma of human norovirus infection and immunity
Dr Lijuan Yuan and her team have studied human noroviruses (HuNoV) in gnotobiotic pigs for over 15 years. Here, she explains how such research is advancing our understanding of HuNoV pathogenesis, infectivity, and immunity.
Can we do drug repositioning without disease gene expression?
Chuo University’s Professor Y-h. Taguchi examines the application of cutting-edge single-cell-based measurements in drug repositioning.
Targeting the central nervous system: The future of therapeutic strategies for MS
Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, looks at the future of therapeutic strategies for MS, focusing on targeting the central nervous system.
Decarbonising the world economy with synthetic biology
Macquarie University Distinguished Professor Ian Paulsen, discusses how synthetic biology can be used to decarbonise the global economy.
Sight loss research: Looking forward to an equitable future
Keith Valentine, Chief Executive of Fight for Sight and Vision Foundation, shares how these newly merged organisations are driving efforts in sight loss research to improve patient care.
CB2R agonists in the clinics: A treasure chest for treating inflammatory diseases
Researchers give an update on clinical trials with CB2R agonists and their potential for the treatment of inflammatory diseases.
Development of a new gene therapy drug as a treatment for hypophosphatasia
The current primary treatment for hypophosphatasia is enzyme replacement therapy; however the development of a new gene therapy drug, ARU-2801, may change the landscape forever.
The next frontier in anti-cancer drugs
Dr Anthony J. Berdis, Case Comprehensive Cancer Center discusses the future of cancer treatments and anti-cancer drugs.